TheraCryf Advances Orexin-1 Receptor Antagonist for Addiction Treatment with Korean Patent Grant and Manufacturing Milestones
Key Insights
TheraCryf (search) received a Korean patent grant for its Orexin-1R antagonist (search) in addiction (search), completing broad intellectual property coverage across major commercial markets including the US and EU.
The company achieved its first manufacturing milestone ahead of schedule, successfully scaling up production from gram quantities to 0.5kg and initiating 2kg human-grade material manufacturing.
An optimal formulation using Amorphous Solid Dispersions has been identified, enabling a straightforward drug-in-capsule approach for first-in-human studies with enhanced oral absorption.
TheraCryf (search) plc has secured a Korean patent grant for its Orexin-1 receptor (search) antagonist targeting addiction (search) and achieved significant manufacturing milestones, positioning the clinical-stage drug development company closer to first-in-human trials for its lead brain disorder program.
Patent Protection Strengthens Global IP Portfolio
The Korean Intellectual Property Office (KIPO) granted TheraCryf (search) a patent for its Orexin-1R antagonist (search) in addiction (search), providing composition of matter coverage—the strongest form of patent protection available. This grant complements the company's existing intellectual property coverage across major commercial markets including the United States, European Union, and other Asian territories.
Dr. Helen Kuhlman, Chief Operating Officer of TheraCryf (search), noted that "our Intellectual Property cover for all major territories for our lead programme in addiction (search) is very nearly complete."
Manufacturing Scale-Up Exceeds Timeline Expectations
TheraCryf (search) achieved its first manufacturing milestone ahead of schedule, successfully scaling up compound production from small gram quantities to 0.5kg. The company has also initiated manufacturing of 2kg human-grade material and continues progressing with its planned 10kg manufacturing scale-up.
The successful scale-up represents a significant milestone for the Alderley Park-based company. After formulation to the optimal dosage form, the 0.5kg batch will be used in an in vivo study to identify the therapeutic index—the range between therapeutic effect and the highest dose before harmful effects are observed. This data will inform dosing for the critical 28-day toxicology studies scheduled to commence in early 2026.
Optimal Formulation Identified for Clinical Development
The company has identified an optimal formulation of its lead compound through screening of multiple potential Amorphous Solid Dispersions (ASD) in vitro, followed by in vivo pharmacokinetics studies. The chosen formulation offers several advantages for clinical development, including enhanced oral absorption and exposure, which means less product will be required to achieve the blood levels needed for potential effectiveness.
The formulation enables utilization of a straightforward drug-in-capsule drug delivery approach for first-in-human studies, simplifying the path to clinical testing.
Regulatory Pathway Advances with Species Selection
TheraCryf (search) has confirmed selection of a non-rodent species for the required 28-day repeated dose toxicity studies after the lead compound exhibited highly favorable handling properties when tested in vivo for the first time in this alternative species. The selected species has comparability with human metabolism and is accepted by major regulatory agencies.
Data from these toxicology studies will form an essential element of the clinical trial application planned for next year.
GMP Manufacturing Initiated for Human Studies
Through its partnership with Pharmaron, TheraCryf (search) has initiated work to manufacture drug product for human use in Phase 1 healthy volunteer studies. This process is conducted under Good Manufacturing Practice (GMP) conditions, a regulatory standard ensuring safety and quality for human administration. Data from this activity will form part of the regulatory package required for the clinical trial application.
Comprehensive Development Pipeline
TheraCryf (search) maintains a broad clinical and preclinical pipeline addressing brain disorders including addiction (search), anxiety (search), fatigue (search), narcolepsy (search), glioblastoma (search), and neurodevelopmental disorders (search). The company's strategy focuses on generating compelling datasets to preclinical and clinical proof of concept before partnering with mid-size to large pharmaceutical companies for larger trials and commercialization.
Kuhlman expressed confidence in the program's trajectory, stating, "We remain confident that we are on target to achieve the data required to support a clinical trial submission for this exciting programme according to the plan we have outlined."
The company anticipates providing updates on completion of the 10kg manufacturing scale-up campaign, dose range finding studies, initiation and completion of regulatory standard 28-day toxicology studies, and interactions with regulatory agencies in preparation for clinical trial applications.